small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 52 results

Industry

Healthcare

Region

Europe

Winston has a well-established presence in Europe representing clients for over three decades. We demonstrate excellence advising clients on transactional, disputes and regulatory matters in the financial services, private equity, industrial, health, and technology sectors. Our European offices bring together a unique blend of deep local knowledge and global expertise, allowing us to effectively navigate complex cross-border legal matters. ...Read more

Practice Area

Government Program Fraud, False Claims Act & Qui Tam Litigation

Investigations and litigation involving alleged fraud against the government pose a significant and growing threat to organizations and individuals across all industries that engage directly or indirectly in business with federal, state, and/or local governments. The government makes aggressive use of its extensive criminal and civil investigatory powers to root out alleged fraud and abuse implicating government funds, including one of its most powerful civil enforcement tools—the federal False Claims Act (FCA)—and similar state false claims statutes....Read more

Experience 39 results

Experience

|

January 22, 2026

Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)

Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters....Read more

Experience

|

January 5, 2026

Winston advised ODDO BHF “Strategic Opportunities” on its investment in Groupe Hueber Assurances

Winston & Strawn LLP Paris advised ODDO BHF “Strategic Opportunities” on its investment in Groupe Hueber Assurances, a leading player in digital insurance brokerage, notably in health and pet insurance....Read more

Experience

|

April 11, 2025

Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering

Winston & Strawn is serving as underwriters counsel to R.F. Lafferty in connection with Cuprina Holdings, a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, in its announced closing of $12,000,000 initial public offering. The Offering consists of 3,000,000 ordinary shares at a public offering price of $4 per share, for total gross proceeds of $12,000,000, before deducting underwriting discounts and offering expenses....Read more
View All Experience

Insights & News 1,197 results

Sponsorship

|

March 23, 2026

Winston & Strawn Sponsors Healthcare Business International (HBI) 2026

We are proud to be an Elite Sponsor of the 2026 Healthcare Business International Conference in Paris. This must-attend event brings together leading decision-makers from the global for-profit healthcare sector to explore new business opportunities, drive growth, and shape the future of healthcare....Read more

News

|

March 19, 2026

|

7 Min Read

Law Firms: The Next Frontier for Private Equity in Professional Services?

Law firms are one of the last major professional services segments without meaningful private equity (PE) penetration. The core investment attributes are familiar:...Read more

Client Alert

|

March 9, 2026

|

3 Min Read

OIG Special Advisory Bulletin Addresses Direct-to-Consumer Prescription Drug Sales and Provides a Framework for Compliant Programs

On January 27, 2026, the U.S. Department of Health and Human Services Office of Inspector General (the OIG) issued a Special Advisory Bulletin (the Bulletin) addressing the application of the federal anti-kickback statute (the AKS) to direct-to-consumer (DTC) prescription drug sales. 

The Bulletin, the OIG’s first Special Advisory Bulletin since September 2014, was issued in response to the proliferation of DTC programs. The Bulletin, which sets forth the framework under which a manufacturer’s DTC program presents a low risk of violating the AKS, is viewed by the growing DTC industry as favorable guidance. DTC programs offering modern weight-loss medications, such as GLP-1 drugs, are becoming increasingly popular, and the Bulletin provides a helpful framework to support the viability of these programs. 

View All Insights & News

Other Results 39 results

Site Content

What Is Healthcare Security Law?

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) established U.S. regulations to protect the privacy and security of individual health information. The healthcare security law creates these specific protections through both the HIPAA Privacy Rule and the HIPAA Security Rule. The Privacy Rule has set national standards for the protection of certain types of health information. The Security Rule established security standards for protecting consumers’ health information that is stored or transferred electronically. The healthcare Security Rule outlines the operational safeguards that organizations must implement to keep protected electronic health information secure....Read more

Site Content

What Is Healthcare Privacy Law?

Today, healthcare privacy law is driven by the 1996 Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. This federal privacy rule establishes protections for specific patient health information. Healthcare plans, clearinghouses, and providers are subject to the law....Read more

Site Content

Japan Practice

Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising